{"id":873652,"date":"2025-08-09T07:44:27","date_gmt":"2025-08-09T11:44:27","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/srpt-news-did-sarepta-therapeutics-mislead-investors-contact-bfa-law-by-august-25-class-action-deadline-nasdaqsrpt\/"},"modified":"2025-08-09T07:44:27","modified_gmt":"2025-08-09T11:44:27","slug":"srpt-news-did-sarepta-therapeutics-mislead-investors-contact-bfa-law-by-august-25-class-action-deadline-nasdaqsrpt","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/srpt-news-did-sarepta-therapeutics-mislead-investors-contact-bfa-law-by-august-25-class-action-deadline-nasdaqsrpt\/","title":{"rendered":"SRPT NEWS: Did Sarepta Therapeutics Mislead Investors? Contact BFA Law by August 25 Class Action Deadline (NASDAQ:SRPT)"},"content":{"rendered":"
\n

NEW YORK, Aug. 09, 2025 (GLOBE NEWSWIRE) — Leading securities law firm Bleichmar Fonti & Auld LLP<\/strong><\/a> announces that a lawsuit has been filed against Sarepta Therapeutics, Inc. (NASDAQ: SRPT) and certain of the Company\u2019s senior executives for potential violations of the federal securities laws.<\/p>\n

If you invested in Sarepta, you are encouraged to obtain additional information by visiting: https:\/\/www.bfalaw.com\/cases-investigations\/sarepta-therapeutics-inc-class-action<\/strong><\/a>.<\/p>\n

Investors have until August 25, 2025, to ask the Court to be appointed to lead the case. The complaint asserts claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors who purchased Sarepta securities. The case is pending in the U.S. District Court for the Southern District of New York and is captioned Dolgicer v. Sarepta Therapeutics, Inc., et al.<\/em>, No. 25-cv-05317.<\/p>\n

\n Why Was Sarepta Sued for Securities Fraud? <\/strong>\n <\/p>\n

Sarepta is a biopharmaceutical company focused on developing treatments for rare diseases. Sarepta\u2019s most important product is Elevidys, a therapy for the treatment of Duchenne muscular dystrophy. As alleged, Sarepta repeatedly touted the safety profile of Elevidys and told investors that the benefits of the treatment outweighed its risks.<\/p>\n

In truth, Elevidys causes fatal acute liver failure in some patients.<\/p>\n

\n The Stock Declines as the Truth Is Revealed<\/strong>\n <\/p>\n

On March 18, 2025, Sarepta announced that a patient that had been treated with Elevidys died after suffering acute liver failure. On this news, the price of Sarepta stock fell $27.81 per share, or over 27%, from $101.35 per share on March 17, 2025, to $73.54 per share on March 18, 2025. Nevertheless, on the same day, Sarepta assured investors that \u201cthe benefit-risk of ELEVIDYS remains positive.\u201d<\/p>\n

Next, on June 15, 2025, Sarepta announced that a second patient treated with Elevidys had died from acute liver failure and that it was suspending certain shipments of Elevidys and paused dosing in an ongoing clinical trial of the treatment. On this news, the price of Sarepta stock fell $15.24 per share, or more than 42%, from $36.18 per share on June 13, 2025, to $20.94 per share on June 16, 2025.<\/p>\n

Finally, on July 17, 2025, Sarepta revealed that a third patient treated with one of Sarepta\u2019s investigational treatments related to Elevidys had died from acute liver failure in June 2025. On this news, the price of Sarepta stock fell more than 40% on July 18, 2025.<\/p>\n

\n Click here for more information: <\/strong>
\n
\n https:\/\/www.bfalaw.com\/cases-investigations\/sarepta-therapeutics-inc-class-action<\/strong>
\n <\/a>
\n .<\/strong>\n <\/p>\n

\n What Can You Do?<\/strong>\n <\/p>\n

If you invested in Sarepta you may have legal options and are encouraged to submit your information to the firm.<\/p>\n

All representation is on a contingency fee basis, there is no cost to you. Shareholders are not responsible for any court costs or expenses of litigation. The firm will seek court approval for any potential fees and expenses.<\/p>\n

\n Submit your information by visiting:<\/strong>\n <\/p>\n

\n
\n https:\/\/www.bfalaw.com\/cases-investigations\/sarepta-therapeutics-inc-class-action<\/strong>
\n <\/a>\n <\/p>\n

Or contact:
Ross Shikowitz
ross@bfalaw.com<\/a>
212.789.3619<\/p>\n

\n Why Bleichmar Fonti & Auld LLP?<\/strong>\n <\/p>\n

BFA is a leading international law firm representing plaintiffs in securities class actions and shareholder litigation. It has been named a top plaintiff law firm by Chambers USA<\/em>, The Legal 500<\/em>, and ISS SCAS<\/em>, and its attorneys have been named \u201cElite Trial Lawyers\u201d by the National Law Journal<\/em>, among the top \u201c500 Leading Plaintiff Financial Lawyers\u201d by Lawdragon<\/em>, \u201cTitans of the Plaintiffs\u2019 Bar\u201d by Law360<\/em> and \u201cSuperLawyers\u201d by Thomson Reuters. Among its recent notable successes, BFA recovered over $900 million in value from Tesla, Inc.\u2019s Board of Directors, as well as $420 million from Teva Pharmaceutical Ind. Ltd.<\/p>\n

For more information about BFA and its attorneys, please visit https:\/\/www.bfalaw.com<\/a>.<\/p>\n

\n
\n https:\/\/www.bfalaw.com\/cases-investigations\/sarepta-therapeutics-inc-class-action<\/strong>
\n <\/a>\n <\/p>\n

\n Attorney advertising. Past results do not guarantee future outcomes.<\/em>\n <\/p>\n

\"\"
\n
\n \"\"\n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

NEW YORK, Aug. 09, 2025 (GLOBE NEWSWIRE) — Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Sarepta Therapeutics, Inc. (NASDAQ: SRPT) and certain of the Company\u2019s senior executives for potential violations of the federal securities laws. If you invested in Sarepta, you are encouraged to obtain additional information by visiting: https:\/\/www.bfalaw.com\/cases-investigations\/sarepta-therapeutics-inc-class-action. Investors have until August 25, 2025, to ask the Court to be appointed to lead the case. The complaint asserts claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors who purchased Sarepta securities. The case is pending in the U.S. District Court for the Southern District of New York and is captioned … <\/p>\n

Continue reading “SRPT NEWS: Did Sarepta Therapeutics Mislead Investors? Contact BFA Law by August 25 Class Action Deadline (NASDAQ:SRPT)”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-873652","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nSRPT NEWS: Did Sarepta Therapeutics Mislead Investors? Contact BFA Law by August 25 Class Action Deadline (NASDAQ:SRPT) - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/srpt-news-did-sarepta-therapeutics-mislead-investors-contact-bfa-law-by-august-25-class-action-deadline-nasdaqsrpt\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"SRPT NEWS: Did Sarepta Therapeutics Mislead Investors? Contact BFA Law by August 25 Class Action Deadline (NASDAQ:SRPT) - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"NEW YORK, Aug. 09, 2025 (GLOBE NEWSWIRE) — Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Sarepta Therapeutics, Inc. (NASDAQ: SRPT) and certain of the Company\u2019s senior executives for potential violations of the federal securities laws. If you invested in Sarepta, you are encouraged to obtain additional information by visiting: https:\/\/www.bfalaw.com\/cases-investigations\/sarepta-therapeutics-inc-class-action. Investors have until August 25, 2025, to ask the Court to be appointed to lead the case. The complaint asserts claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors who purchased Sarepta securities. The case is pending in the U.S. District Court for the Southern District of New York and is captioned … Continue reading "SRPT NEWS: Did Sarepta Therapeutics Mislead Investors? Contact BFA Law by August 25 Class Action Deadline (NASDAQ:SRPT)"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/srpt-news-did-sarepta-therapeutics-mislead-investors-contact-bfa-law-by-august-25-class-action-deadline-nasdaqsrpt\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-08-09T11:44:27+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTUwODU1MSM3MDg4NjA1IzIyOTA5OTU=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/srpt-news-did-sarepta-therapeutics-mislead-investors-contact-bfa-law-by-august-25-class-action-deadline-nasdaqsrpt\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/srpt-news-did-sarepta-therapeutics-mislead-investors-contact-bfa-law-by-august-25-class-action-deadline-nasdaqsrpt\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"SRPT NEWS: Did Sarepta Therapeutics Mislead Investors? Contact BFA Law by August 25 Class Action Deadline (NASDAQ:SRPT)\",\"datePublished\":\"2025-08-09T11:44:27+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/srpt-news-did-sarepta-therapeutics-mislead-investors-contact-bfa-law-by-august-25-class-action-deadline-nasdaqsrpt\\\/\"},\"wordCount\":605,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/srpt-news-did-sarepta-therapeutics-mislead-investors-contact-bfa-law-by-august-25-class-action-deadline-nasdaqsrpt\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTUwODU1MSM3MDg4NjA1IzIyOTA5OTU=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/srpt-news-did-sarepta-therapeutics-mislead-investors-contact-bfa-law-by-august-25-class-action-deadline-nasdaqsrpt\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/srpt-news-did-sarepta-therapeutics-mislead-investors-contact-bfa-law-by-august-25-class-action-deadline-nasdaqsrpt\\\/\",\"name\":\"SRPT NEWS: Did Sarepta Therapeutics Mislead Investors? Contact BFA Law by August 25 Class Action Deadline (NASDAQ:SRPT) - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/srpt-news-did-sarepta-therapeutics-mislead-investors-contact-bfa-law-by-august-25-class-action-deadline-nasdaqsrpt\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/srpt-news-did-sarepta-therapeutics-mislead-investors-contact-bfa-law-by-august-25-class-action-deadline-nasdaqsrpt\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTUwODU1MSM3MDg4NjA1IzIyOTA5OTU=\",\"datePublished\":\"2025-08-09T11:44:27+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/srpt-news-did-sarepta-therapeutics-mislead-investors-contact-bfa-law-by-august-25-class-action-deadline-nasdaqsrpt\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/srpt-news-did-sarepta-therapeutics-mislead-investors-contact-bfa-law-by-august-25-class-action-deadline-nasdaqsrpt\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/srpt-news-did-sarepta-therapeutics-mislead-investors-contact-bfa-law-by-august-25-class-action-deadline-nasdaqsrpt\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTUwODU1MSM3MDg4NjA1IzIyOTA5OTU=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTUwODU1MSM3MDg4NjA1IzIyOTA5OTU=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/srpt-news-did-sarepta-therapeutics-mislead-investors-contact-bfa-law-by-august-25-class-action-deadline-nasdaqsrpt\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"SRPT NEWS: Did Sarepta Therapeutics Mislead Investors? Contact BFA Law by August 25 Class Action Deadline (NASDAQ:SRPT)\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"SRPT NEWS: Did Sarepta Therapeutics Mislead Investors? Contact BFA Law by August 25 Class Action Deadline (NASDAQ:SRPT) - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/srpt-news-did-sarepta-therapeutics-mislead-investors-contact-bfa-law-by-august-25-class-action-deadline-nasdaqsrpt\/","og_locale":"en_US","og_type":"article","og_title":"SRPT NEWS: Did Sarepta Therapeutics Mislead Investors? Contact BFA Law by August 25 Class Action Deadline (NASDAQ:SRPT) - Market Newsdesk","og_description":"NEW YORK, Aug. 09, 2025 (GLOBE NEWSWIRE) — Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Sarepta Therapeutics, Inc. (NASDAQ: SRPT) and certain of the Company\u2019s senior executives for potential violations of the federal securities laws. If you invested in Sarepta, you are encouraged to obtain additional information by visiting: https:\/\/www.bfalaw.com\/cases-investigations\/sarepta-therapeutics-inc-class-action. Investors have until August 25, 2025, to ask the Court to be appointed to lead the case. The complaint asserts claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors who purchased Sarepta securities. The case is pending in the U.S. District Court for the Southern District of New York and is captioned … Continue reading \"SRPT NEWS: Did Sarepta Therapeutics Mislead Investors? Contact BFA Law by August 25 Class Action Deadline (NASDAQ:SRPT)\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/srpt-news-did-sarepta-therapeutics-mislead-investors-contact-bfa-law-by-august-25-class-action-deadline-nasdaqsrpt\/","og_site_name":"Market Newsdesk","article_published_time":"2025-08-09T11:44:27+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTUwODU1MSM3MDg4NjA1IzIyOTA5OTU=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/srpt-news-did-sarepta-therapeutics-mislead-investors-contact-bfa-law-by-august-25-class-action-deadline-nasdaqsrpt\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/srpt-news-did-sarepta-therapeutics-mislead-investors-contact-bfa-law-by-august-25-class-action-deadline-nasdaqsrpt\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"SRPT NEWS: Did Sarepta Therapeutics Mislead Investors? Contact BFA Law by August 25 Class Action Deadline (NASDAQ:SRPT)","datePublished":"2025-08-09T11:44:27+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/srpt-news-did-sarepta-therapeutics-mislead-investors-contact-bfa-law-by-august-25-class-action-deadline-nasdaqsrpt\/"},"wordCount":605,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/srpt-news-did-sarepta-therapeutics-mislead-investors-contact-bfa-law-by-august-25-class-action-deadline-nasdaqsrpt\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTUwODU1MSM3MDg4NjA1IzIyOTA5OTU=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/srpt-news-did-sarepta-therapeutics-mislead-investors-contact-bfa-law-by-august-25-class-action-deadline-nasdaqsrpt\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/srpt-news-did-sarepta-therapeutics-mislead-investors-contact-bfa-law-by-august-25-class-action-deadline-nasdaqsrpt\/","name":"SRPT NEWS: Did Sarepta Therapeutics Mislead Investors? Contact BFA Law by August 25 Class Action Deadline (NASDAQ:SRPT) - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/srpt-news-did-sarepta-therapeutics-mislead-investors-contact-bfa-law-by-august-25-class-action-deadline-nasdaqsrpt\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/srpt-news-did-sarepta-therapeutics-mislead-investors-contact-bfa-law-by-august-25-class-action-deadline-nasdaqsrpt\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTUwODU1MSM3MDg4NjA1IzIyOTA5OTU=","datePublished":"2025-08-09T11:44:27+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/srpt-news-did-sarepta-therapeutics-mislead-investors-contact-bfa-law-by-august-25-class-action-deadline-nasdaqsrpt\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/srpt-news-did-sarepta-therapeutics-mislead-investors-contact-bfa-law-by-august-25-class-action-deadline-nasdaqsrpt\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/srpt-news-did-sarepta-therapeutics-mislead-investors-contact-bfa-law-by-august-25-class-action-deadline-nasdaqsrpt\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTUwODU1MSM3MDg4NjA1IzIyOTA5OTU=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTUwODU1MSM3MDg4NjA1IzIyOTA5OTU="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/srpt-news-did-sarepta-therapeutics-mislead-investors-contact-bfa-law-by-august-25-class-action-deadline-nasdaqsrpt\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"SRPT NEWS: Did Sarepta Therapeutics Mislead Investors? Contact BFA Law by August 25 Class Action Deadline (NASDAQ:SRPT)"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/873652","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=873652"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/873652\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=873652"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=873652"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=873652"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}